Loading...

TNXP TONIX PHARMACEUTICALS HOLDING CORP Earnings Reports 8-K Filing

TNX

TNXP

TONIX PHARMACEUTICALS HOLDING CORP

(TNXP)

2024 8-K

Show Summary

Show Summary

New Product Launches

Equity Offerings

Product Expansion

Financial Statements

Reverse Stock Split

Product Expansion

Financial Statements

Product Expansion

Research Collaboration

Earnings Report

Management Change

Conference Presentation

NASDAQ Compliance

Financial Update

Positive Trial Results

Management Change

Loan Termination & Split

Management Change

FDA Approval Date

Share Offering Increase

FDA Application Accepted

Management Changes

Leadership Expansion

Vaccine Data Release

Quarterly Results

Research Partnership

Vaccine Presentation

Shareholder Meeting

Q3 2024 Results

Funding Announcement

FDA Application

AI Collaboration

Patent Issuance

Product Presentation

Vaccine Alignment

Management Change

Vaccine Presentation

Share Repurchase

Share Offering Increase

Vaccine Collaboration

Clinical Trial Update

Quarterly Results

Results of Operations and F...

Sales Agreement

FDA Fast Track Designation ...

Decommissioning of Facility

Agreement for Public Offering

FDA Meeting for Tonmya NDA

Agreement with Defense Thre...

Compliance with NASDAQ List...

FDA Meeting for Tonmya Prod...

Amendment to Filing

Agreement for Public Offering

Reverse Stock Split

Data Announcement

Data from Phase 3 RESILIENT...

Data Announcement

Workforce Reduction and Dec...

ASCP Annual Meeting Present...

Market Assessment Results

Earnings Reports

Earnings Report

Securities Purchase Agreement

FDA Designation for TNX-290...

Poster Presentation at ACS ...

Selection of Contract Manuf...

Quantitative Data

Additional Efficacy Data An...

Publication of Research Paper

Investment Support for Tonm...

Announcement of TNX-1500 Ph...

Product Trial Completion

Clinical Study Results

Shareholder Approval

Engagement of Rho for NDA s...

FDA Clearance for OASIS Trial

Research Findings on Long C...

FDA Acceptance of Trade Name

Amendment to Articles of In...

Workforce Reduction

Additional Data Announcement

Update & FDA Decision

Securities Purchase Agreement

Positive Clinical Trial Res...

FDA Clearance for TNX-2900 ...

Enrollment in Phase 2 study...

Earnings Report

Clinical Trial with TNX-180...

Discontinuation of TNX-601 ...

Data from oral presentation...

Notice from Nasdaq

Presentation at World Vacci...

Clinical Phase Completion

Securities Purchase Agreement

Update of Investor Presenta...

Research Results Announcement

Data Announcement

FDA Feedback on Vaccine Can...

Phase 1 Study Initiation

Earnings Reports

Regulation FD Disclosure

Clinical Study Completion

Phase 3 trial completion

Enrollment in Phase 2 Study

Securities Purchase Agreement

Prioritization of TNX-4300 ...

New Product Launches

Enrollment in Phase 2 study...

Asset Acquisitions

Regulation FD Disclosure

Asset Purchase Agreement

Product Launches

Data Announcement

Data Presentation

Presentation Update

Announcement of Presentatio...

Compliance Regained

Poster Presentation at ASCP...

Discovery of Isomers and De...

Research Collaboration Agre...

Reverse Stock Split

Earnings Reports

Annual Meeting of Shareholders

FDA Clears IND Application ...

Update of Presentations

Research Results Presentation

Publication of Articles on ...

Clinical Trials Update

Presentation of Vaccine Dev...

Research Results Announcement

Nasdaq Compliance Notice

Presentation on TNX-2900 data

Presentation Update

Enrollment in Phase 2 UPLIF...

Regulation FD Disclosure

Financial Results

Preclinical Results of mTNX...

Presentation Update

Appointment of Director

License Agreement

Conference Presentation

Enrollment in Phase 2 PREVE...

Acquisition of Healion Bio,...

Research Agreement with Uni...

Data Presentation on Migrai...

Compliance Regained

Announcement of Antiviral S...

Financial Results

Publication of Paper on Scr...

Presentation at Biotech Sho...

Appointment of Dr. Zeil Ros...

External Links:

Tonix Pharmaceuticals Holding Corp. discloses preliminary operating results for Q2 2024, including net cash used in operating activities of $12.9 million and net revenue of $2.2 million. The company's cash resources and equity offering proceeds may n

AI Assistant

TONIX PHARMACEUTICALS HOLDING CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.